The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|March 6, 2014
KCR Expands in UK & Germany and Moves on to France
Author(s)Philip Ward
KCR has opened new offices in London and Berlin, and is now turning its attention to France.
Advertisement
KCR, the CRO operating in 18 countries in Europe as well as the US, has opened new offices in London and Berlin, and is now turning its attention to France.
“I am very excited seeing KCR strengthening its visibility across Western Europe, particularly in the UK and Germany, where we have already been enjoying partnerships with locally based or represented companies,” says Mike Jagielski, CEO of KCR. “Having our own entities registered in these countries will make our collaboration even stronger. It will also equip KCR with local law benefits and make our business cooperation easier. The next country we will aim for is France.”
KCR has operated in Central and Eastern Europe and the Commonwealth of Independent States since 1997. Having a local team in each of the offices gives the company insight into local regulations, and has also helped to build extensive relationships with key opinion leaders and principal investigators, according to the CRO.
KCR offers three types of professional contract research services: clinical development services, functional service provision and post-marketing clinical services, in a wide spectrum of therapeutic areas.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5